Market cap
$4,683 Mln
Revenue (TTM)
$575 Mln
P/E Ratio
--
P/B Ratio
10.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
46.09
-
EV/EBITDA
1575.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.4
-
Face value
--
-
Shares outstanding
58,563,600
6 Years Aggregate
CFO
$33.53 Mln
EBITDA
$9.96 Mln
Net Profit
$-19.33 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Inari Medical Inc (NARI)
| 56.7 | 0.5 | 55.8 | 36.8 | 2.7 | -- | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Inari Medical Inc (NARI)
| -21.2 | 2.1 | -30.4 | 4.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Inari Medical Inc (NARI)
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core,... capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. As of February 19, 2025, Inari Medical, Inc. operates as a subsidiary of Stryker Corporation. Read more
-
CEO, President & Director
Mr. Andrew J. Hykes
-
CEO, President & Director
Mr. Andrew J. Hykes
-
Headquarters
Irvine, CA
-
Website
FAQs for Inari Medical Inc (NARI)
What is the current share price of Inari Medical Inc (NARI) Today?
The share price of Inari Medical Inc (NARI) is $79.97 (NASDAQ) as of 19-Feb-2025 09:30 EDT. Inari Medical Inc (NARI) has given a return of 2.68% in the last 3 years.
What is the current PB & PE ratio of Inari Medical Inc (NARI)?
Since, TTM earnings of Inari Medical Inc (NARI) is negative, P/E ratio is not available.
The P/B ratio of Inari Medical Inc (NARI) is 10.77 times as on 19-Feb-2025, a 184 premium to its peers’ median range of 3.79 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-2,287.26 |
8.05 |
2022 |
-116.43 |
8.17 |
2021 |
515.97 |
21.22 |
2020 |
349.57 |
24.07 |
2019 |
-- |
-- |
What is the 52 Week High and Low of Inari Medical Inc (NARI)?
The 52-week high and low of Inari Medical Inc (NARI) are Rs -- and Rs -- as of 06-Sep-2026.
What is the market cap of Inari Medical Inc (NARI)?
Inari Medical Inc (NARI) has a market capitalisation of $ 4,683 Mln as on 19-Feb-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Inari Medical Inc (NARI)?
Before investing in Inari Medical Inc (NARI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.